drugset / Trial / NCT04520490
Brain Activation and Satiety in Children 2
Phase 3
Active not recruiting
63 enrolled
Seattle Children's Hospital
University of Washington · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
Timeline
- Start
- 2021-01-28
- Primary completion
- 2025-08-21
- Completion
- 2026-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Exenatide | Peptide | 2 mg | Subcutaneous |
Indications
No indication recorded.